Our previous research indicated that RFX1 contributed to the overexpression of TLR4 and the activation of CD14+ monocytes in CAD patients by altering DNA methylation and histone modifications in the TLR4 promoter region (Du et al., 2019). This evidence concerns the gene RFX1 and coronary artery disorder.